TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7859889

Group type: EXPERIMENTAL
Intervention: Mean total urinary iodine excretion (UIT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mean urinary iodine concentration (UIC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Correlation of UIT with serum nonhormonal iodine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Correlation of UIC with serum nonhormonal iodine
Number of subjects: 120

Group type: COMPARATOR
Intervention: UIT in the 3rd decade compared to the 6th decade
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: UIT increase with age up to the 6th decade
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Distribution of UIT
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rates of renal iodine clearance (UIC/SNI) in the 6th decade
Number of subjects: 120
Study: 1701715

Group type: EXPERIMENTAL
Intervention: Mechanical tap to the fifth finger (targets)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical tap to the second finger (standards)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical tap to the third or fourth finger (tactile novels)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electric shock at the wrist (shock novels)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P300 amplitude to shock and tactile novel stimuli
Number of subjects: 0
Study: 216264

Group type: EXPERIMENTAL
Intervention: Proflavine
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 30974479

Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy (CFT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Manual Therapy and Exercise (MT-EX)
Number of subjects: 121
Study: 28750061

Group type: EXPERIMENTAL
Intervention: Winning condition in individual competition (men)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Winning condition in team competition (women)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Losing condition in team competition (men)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Implicit motive nPower in women (naturally cycling) after winning
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Implicit motive nPower in women (naturally cycling) after losing
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Implicit motive nPower in men after losing
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Implicit motive nPower in men after winning
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Implicit motive nPower in male teams after losing
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Implicit motive nPower in individual competitions (women)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Implicit motive nAffiliation in women competing as teams
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Implicit motive nAffiliation in women competing individually
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Aggression in men, losers, and teams
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Aggression in women competing individually
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Aggression in women competing as teams and in men generally
Number of subjects: 326
Study: 24952472

Group type: EXPERIMENTAL
Intervention: Individualized out-of-home activity intervention delivered by volunteers (once a week for 3 months)
Number of subjects: 121
Study: 24280463

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 29

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 29
Study: 21446235

Group type: EXPERIMENTAL
Intervention: Hood nebulization of 0.30 mg/kg salbutamol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Mask nebulization of 0.30 mg/kg salbutamol
Number of subjects: 26
Study: 19371494

Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 341
Study: 16411994

Group type: EXPERIMENTAL
Intervention: First trimester ultrasound dating scan (scan group) between 8 and 12 weeks, measuring crown‐rump length.
Number of subjects: 463

Group type: COMPARATOR
Intervention: No ultrasound dating scan (no-scan group), gestation determined using last menstrual period (LMP).
Number of subjects: 463
Study: 16786214

Group type: EXPERIMENTAL
Intervention: Prednisolone 0.75 mg/Kg/day
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no prednisolone)
Number of subjects: 67
Study: 12768947

Group type: EXPERIMENTAL
Intervention: Intramuscular penicillin
Number of subjects: 1707

Group type: COMPARATOR
Intervention: 2-weekly intramuscular penicillin
Number of subjects: 1707

Group type: COMPARATOR
Intervention: 3-weekly intramuscular penicillin
Number of subjects: 1707
Study: 10547167

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg twice daily) and clarithromycin (500 mg three times daily) for 14 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Persistent H. pylori infection
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Successful eradication of H. pylori
Number of subjects: 100
Study: 8933774

Group type: EXPERIMENTAL
Intervention: Brompheniramine 12 mg
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 1831533

Group type: EXPERIMENTAL
Intervention: Intratumoral injection of OK‐432
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intratumoral injection of physiological saline
Number of subjects: 25

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 25
Study: 6137325

Group type: EXPERIMENTAL
Intervention: Furosemide, 80 mg/day; Chlorthalidone, 100 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chlorthalidone, 100 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tienilic acid, 250 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clopamide, 5 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Muzolimine, 20 to 40 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Indapamide, 2.5 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Chlorthalidone, 100 mg/day + beta-blocker (propranolol or atenolol)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clopamide + beta-blocker (pindolol, 10 mg/day)
Number of subjects: 16
Study: 31828602

Group type: EXPERIMENTAL
Intervention: Cortical magnetic stimulation (Subgroup A-I and B-I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sacral magnetic stimulation (Subgroup A-II and B-II)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Subgroup A-II and B-II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Incontinence Quality of Life (I-QOL) questionnaire
Number of subjects: 40
Study: 30261903

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sildenafil 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sildenafil (3 times daily from 3 days before planned delivery until actual delivery)
Number of subjects: 0
Study: 28298777

Group type: EXPERIMENTAL
Intervention: Articaine buccal infiltration
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lignocaine conventional anesthesia (control group)
Number of subjects: 90
Study: 26187260

Group type: EXPERIMENTAL
Intervention: IIV-HD
Number of subjects: 1000
Study: 23054175

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment (CBT) added to managed care
Number of subjects: 154

Group type: COMPARATOR
Intervention: Managed care only
Number of subjects: 154
Study: 21436594

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 326

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 326
Study: 18641709

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IM training)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (minimal inspiratory load)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 30
Study: 16972832

Group type: EXPERIMENTAL
Intervention: Capsicum plaster at Zusanli acupoints
Number of subjects: 108

Group type: COMPARATOR
Intervention: Capsicum plaster on shoulders (Sham)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo tape at Zusanli acupoints and on shoulder (Control)
Number of subjects: 108
Study: 12719164

Group type: EXPERIMENTAL
Intervention: Active electrical stimulation machine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Dummy machine (no current)
Number of subjects: 34
Study: 11045873

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (COC) pill
Number of subjects: 0
Study: 9326125

Group type: EXPERIMENTAL
Intervention: Advanced pump system that controls both pressure and flow of fluid delivered
Number of subjects: 0

Group type: COMPARATOR
Intervention: Air-driven diaphragm pump that only controls fluid pressure
Number of subjects: 0
Study: 8454328

Group type: EXPERIMENTAL
Intervention: CMR vaccine 30 micrograms
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CMR vaccine 60 micrograms
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CMR vaccine 120 micrograms
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CMR vaccine 240 micrograms
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 3535327

Group type: EXPERIMENTAL
Intervention: 125 micrograms LT4 (group A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 75 micrograms LT4 + 15 micrograms LT3 (group B)
Number of subjects: 54
Study: 29747048

Group type: EXPERIMENTAL
Intervention: Telephone‐based exercise intervention
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: telephone‐based wellness/support intervention
Number of subjects: 450

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 450
Study: 27166295

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir (DRV/r)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 273
Study: 24857356

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pregabalin (PG)
Number of subjects: 200
Study: 22389244

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study: 19883909

Group type: EXPERIMENTAL
Intervention: 16 mm threaded screws
Number of subjects: 432

Group type: COMPARATOR
Intervention: 32 mm threaded screws
Number of subjects: 432
Study: 18940656

Group type: EXPERIMENTAL
Intervention: Phosphate management protocol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 34
Study: 16317122

Group type: EXPERIMENTAL
Intervention: Dietary cholesterol from 3 large eggs (EGG) daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cholesterol-free, fat-free egg substitute (SUB)
Number of subjects: 42
Study: 14669411

Group type: EXPERIMENTAL
Intervention: Palivizumab (Synagis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No protection
Number of subjects: 0
Study: 10804324

Group type: EXPERIMENTAL
Intervention: Lipoprotein(a) concentrations and apolipoprotein(a) molecular weights
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Apo(a) phenotypes determined using 4‐15% sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by immunoblotting
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes population
Number of subjects: 148
Study: 8893979

Group type: EXPERIMENTAL
Intervention: Fuji Type IIIR sealants
Number of subjects: 104

Group type: COMPARATOR
Intervention: Fuji Type IXR sealants
Number of subjects: 104
Study: 1677502

Group type: EXPERIMENTAL
Intervention: ALG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 0
Study: 6341843

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard (control) therapy
Number of subjects: 50
Study: 31826899

Group type: EXPERIMENTAL
Intervention: Patient navigator intervention over 24 months
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Patient navigator intervention
Number of subjects: 300
Study: 29333934

Group type: EXPERIMENTAL
Intervention: 0.2mm skin graft
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 0.3mm skin graft
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 0.4mm skin graft
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 84
Study: 27987585

Group type: EXPERIMENTAL
Intervention: Maintenance erlotinib 150mg/day
Number of subjects: 643

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study: 24811601

Group type: EXPERIMENTAL
Intervention: PRT-201 (low dose)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PRT-201 (medium dose)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PRT-201 (high dose)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 22535259

Group type: EXPERIMENTAL
Intervention: Robotic thyroidectomy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional open thyroidectomy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups (Robotic and Conventional)
Number of subjects: 88
Study: 20102883

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2185

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 2185
Study: 18612728

Group type: EXPERIMENTAL
Intervention: Electronic clinical portfolio
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional paper means
Number of subjects: 100
Study: 15741799

Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 2372

Group type: EXPERIMENTAL
Intervention: Plasminogen
Number of subjects: 2372

Group type: EXPERIMENTAL
Intervention: Factor VII:C
Number of subjects: 2372

Group type: EXPERIMENTAL
Intervention: Lipoprotein (a)
Number of subjects: 2372

Group type: EXPERIMENTAL
Intervention: Factor VII antigen
Number of subjects: 2372

Group type: EXPERIMENTAL
Intervention: None of the measured hemostatic factors
Number of subjects: 2372
Study: 12434288

Group type: EXPERIMENTAL
Intervention: Induced abortion
Number of subjects: 267040

Group type: EXPERIMENTAL
Intervention: Induced abortion after first birth
Number of subjects: 267040

Group type: EXPERIMENTAL
Intervention: Induced abortion after 13 weeks gestation or before first child
Number of subjects: 267040

Group type: COMPARATOR
Intervention: Control group (women without induced abortion)
Number of subjects: 267040
Study: 11310903

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Propofol with EDTA
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (ionised calcium and total magnesium)
Number of subjects: 50
Study: 8804007

Group type: EXPERIMENTAL
Intervention: High flux dialysis membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional dialysis
Number of subjects: 0
Study: 1617983

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 150 mg/kg as a loading dose and then 20 mg/kg/hr for 6 days
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 6367432

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cefaclor and Amoxicillin
Number of subjects: 61
Study: 30852365

Group type: EXPERIMENTAL
Intervention: Self-compassion
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Maladaptive perfectionism
Number of subjects: 302
Study: 29979205

Group type: EXPERIMENTAL
Intervention: Electrotherapy modalities and specific stabilizing exercises (Training group, n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Electrotherapy modalities only (Control group, n = 18)
Number of subjects: 36
Study: 27336868

Group type: EXPERIMENTAL
Intervention: Lornoxicam with 5 mg droperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lornoxicam with 8 mg ondansetron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lornoxicam with 6 mg granisetron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lornoxicam with 5 mg tropisetron
Number of subjects: 0
Study: 25238860

Group type: EXPERIMENTAL
Intervention: Intensive computer-based home training of attention and psychological counselling
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 40
Study: 23015161

Group type: EXPERIMENTAL
Intervention: Computerised anticoagulation management system (DAWN AC)
Number of subjects: 1068

Group type: COMPARATOR
Intervention: Warfarin dosing algorithm
Number of subjects: 1068
Study: 20460558

Group type: EXPERIMENTAL
Intervention: Modified MAI scoring
Number of subjects: 236

Group type: COMPARATOR
Intervention: Beers criteria drug
Number of subjects: 236

Group type: COMPARATOR
Intervention: MAI criteria
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard scoring
Number of subjects: 236
Study: 18946234

Group type: EXPERIMENTAL
Intervention: Montelukast 5mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast 10mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pranlukast 450mg
Number of subjects: 0
Study: 16205886

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (aiming at weight reduction, healthy diet, and increased physical activity)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group (no intensive lifestyle intervention)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (in Turku subgroup)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 321
Study: 12415535

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy delivered over the telephone (IPT-T)
Number of subjects: 30
Study: 12138805

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy with ACE inhibitor perindopril
Number of subjects: 0
Study: 9667344

Group type: COMPARATOR
Intervention: Control Group (CG) - Saline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Neostigmine Group (NG) - 25 microg neostigmine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fentanyl Group (FG) - 25 microg fentanyl
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fentanyl-Neostigmine 10 microg Group (FNG10) - 10 microg fentanyl plus 10 microg neostigmine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fentanyl-Neostigmine 25 microg Group (FNG25) - 25 microg fentanyl plus 25 microg neostigmine
Number of subjects: 50
Study: 7857409

Group type: EXPERIMENTAL
Intervention: Three-dimensional time-of-flight MR angiography
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Three-dimensional phase-contrast MR angiography
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Standard MR imaging
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Transaxial T1 MR imaging
Number of subjects: 35
Study: 2649122

Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine alone (Control)
Number of subjects: 0
Study: 68703

Group type: EXPERIMENTAL
Intervention: Topical nasal spray
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal inhaler
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral syrup formulations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 0
Study: 7263138

Group type: EXPERIMENTAL
Intervention: Low-level transcortical DC-currents (less than 0.3 mA) applied with positive pole at vertex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-level transcortical DC-currents (less than 0.3 mA) applied with negative pole at vertex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-level transcortical DC-currents (less than 0.3 mA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-level transcortical DC-currents
Number of subjects: 0
Study: 31815717

Group type: COMPARATOR
Intervention: Pedometers (PED)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pedometers and Implementation Intentions (PED+II)
Number of subjects: 54
Study: 30173203

Group type: EXPERIMENTAL
Intervention: Non-paranormal framework for estimating causal effects
Number of subjects: 0
Study: 24844540

Group type: EXPERIMENTAL
Intervention: ISNT rule
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: IS rule
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: IS rule (in eyes with CDR >0.57)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Combination of ISNT or IS rule and CDR >0.57
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Cup-to-disc ratio (CDR)
Number of subjects: 244
Study: 25012813

Group type: EXPERIMENTAL
Intervention: Best current care plus a vocational advice service
Number of subjects: 330

Group type: COMPARATOR
Intervention: Best current care
Number of subjects: 330
Study: 22430268

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 229
Study: 19863501

Group type: EXPERIMENTAL
Intervention: Prednisolone (initial dose 0.5‐0.8 mg kg(‐1) daily for 2 weeks followed by placebo for 4 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ciclosporin (2.7‐4.0 mg kg(‐1) daily for 6 weeks)
Number of subjects: 38
Study: 18926586

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 36
Study: 16076686

Group type: COMPARATOR
Intervention: Na-bicarbonate infusion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Na-lactate infusion
Number of subjects: 17
Study: 12680866

Group type: EXPERIMENTAL
Intervention: SIT
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 10477008

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) before radiation therapy (XRT)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Chemotherapy (CT) after radiation therapy (XRT)
Number of subjects: 244
Study: 8965861

Group type: EXPERIMENTAL
Intervention: Zidovudine treatment
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402